tetano
Editor, Senior Moderator
Transplant Proc. 2019 May;51(4):1115-1117. doi: 10.1016/j.transproceed.2019.02.009. Epub 2019 Feb 22.
[h=1]Panel Reactive Antibody Responses Against Influenza Vaccination in Kidney Transplant Recipients.[/h] Khishigsuren B[SUP]1[/SUP], Demir E[SUP]2[/SUP], Akgul SU[SUP]3[/SUP], Temurhan S[SUP]3[/SUP], Ucar AR[SUP]1[/SUP], Dirim AB[SUP]1[/SUP], Catikkas NM[SUP]1[/SUP], Bayraktar A[SUP]4[/SUP], Caliskan Y[SUP]1[/SUP], Yazici H[SUP]1[/SUP], Oguz FS[SUP]3[/SUP], Turkmen A[SUP]1[/SUP], Sever MS[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]INTRODUCTION:[/h] Seasonal influenza is an important cause of morbidity and mortality in the post-transplant period; therefore, the influenza vaccination has been recommended for all kidney transplant recipients before the influenza season. However, at least theoretically, the introduction of antigens via vaccines may trigger rejection attacks by causing an antibody response. In this study, we examined the development of de novo panel reactive antibody (PRA) development against the influenza vaccine in kidney transplant recipients.
[h=4]MATERIALS AND METHODS:[/h] Overall, 41 kidney transplant recipients who received the influenza vaccination and 50 kidney transplant recipients (study group) who refused to receive the influenza vaccination (control group) were enrolled in the study. Following basal biochemistry examination, the inactivated trivalent influenza vaccine was administered intramuscularly. Panel reactive antibodies were screened in all patients before and after vaccination on days 30 and 180. The primary outcome variable was development of de novo panel reactive antibodies.
[h=4]RESULTS:[/h] One patient in the study group developed de novo class I and II PRA at 6 months after vaccination (P > .05), while no antibody development was noted in the control group. Graft dysfunction or biopsy-confirmed rejection was not observed during the follow-up period in both groups.
[h=4]CONCLUSION:[/h] The influenza vaccination is generally effective and safe in solid organ transplant recipients. The vaccination procedure has the potential to trigger antibody development and occurrence of rejection. Therefore, vaccinated kidney transplant recipients should be monitored more carefully with regard to PRA; if the graft deteriorates, a rapid transplant biopsy should be performed.
Copyright ? 2019 Elsevier Inc. All rights reserved.
PMID: 31101183 DOI: 10.1016/j.transproceed.2019.02.009
[h=1]Panel Reactive Antibody Responses Against Influenza Vaccination in Kidney Transplant Recipients.[/h] Khishigsuren B[SUP]1[/SUP], Demir E[SUP]2[/SUP], Akgul SU[SUP]3[/SUP], Temurhan S[SUP]3[/SUP], Ucar AR[SUP]1[/SUP], Dirim AB[SUP]1[/SUP], Catikkas NM[SUP]1[/SUP], Bayraktar A[SUP]4[/SUP], Caliskan Y[SUP]1[/SUP], Yazici H[SUP]1[/SUP], Oguz FS[SUP]3[/SUP], Turkmen A[SUP]1[/SUP], Sever MS[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]INTRODUCTION:[/h] Seasonal influenza is an important cause of morbidity and mortality in the post-transplant period; therefore, the influenza vaccination has been recommended for all kidney transplant recipients before the influenza season. However, at least theoretically, the introduction of antigens via vaccines may trigger rejection attacks by causing an antibody response. In this study, we examined the development of de novo panel reactive antibody (PRA) development against the influenza vaccine in kidney transplant recipients.
[h=4]MATERIALS AND METHODS:[/h] Overall, 41 kidney transplant recipients who received the influenza vaccination and 50 kidney transplant recipients (study group) who refused to receive the influenza vaccination (control group) were enrolled in the study. Following basal biochemistry examination, the inactivated trivalent influenza vaccine was administered intramuscularly. Panel reactive antibodies were screened in all patients before and after vaccination on days 30 and 180. The primary outcome variable was development of de novo panel reactive antibodies.
[h=4]RESULTS:[/h] One patient in the study group developed de novo class I and II PRA at 6 months after vaccination (P > .05), while no antibody development was noted in the control group. Graft dysfunction or biopsy-confirmed rejection was not observed during the follow-up period in both groups.
[h=4]CONCLUSION:[/h] The influenza vaccination is generally effective and safe in solid organ transplant recipients. The vaccination procedure has the potential to trigger antibody development and occurrence of rejection. Therefore, vaccinated kidney transplant recipients should be monitored more carefully with regard to PRA; if the graft deteriorates, a rapid transplant biopsy should be performed.
Copyright ? 2019 Elsevier Inc. All rights reserved.
PMID: 31101183 DOI: 10.1016/j.transproceed.2019.02.009